Eliminación de Identicare Ltd.
UNIDADES ETF DE BAJO ÍNDICE DE CO2 DE DESJARDINS RI USA
$36.77
11:15 02/05/24
PLC DEL GRUPO ANIMALCARE
(la "Compañía" o el "Grupo")
Eliminación de Identicare Ltd.
Material value creation for shareholders from non-core asset
28 febrero 2024. Animalcare Group plc, the international animal health business, announces that it has disposed of its majority shareholding in Identicare Ltd ("Identicare") to BG Bidco 21 Limited, a newly incorporated company owned by funds managed by Bridgepoint Advisors II Limited, for a cash consideration of £24.9m (the "Consideration") payable upon completion of this sale. This represents a significant crystallisation of value for the Company and its shareholders from a non-core asset and allows the Company to focus on growth in its pharmaceutical-based animal health market.
Identicare is a UK-based pet microchipping and pet owner-focused services company. As part of the Group's strategy to focus on pharmaceuticals and to drive growth through launching innovative products, Identicare was separated from the UK pharmaceuticals business within Animalcare Ltd in March 2021, with specialist leadership brought in. The decisions taken by the Company to instil new leadership and with this, a strategic repositioning of the business to make it attractive to specialist investors has enabled Animalcare to today crystallise the value of its investment in Identicare.
Upon receipt of the Consideration and after fees associated with the transaction, the Company's net cash is expected to be around £27.0m.
The disposal of Identicare significantly strengthens the balance sheet of the Group and enables us to accelerate our organic and inorganic growth initiatives and deliver long-term value creation for shareholders. We continue to see a large number of opportunities and this transaction increases our confidence in being able to execute on that pipeline.
The Company expects to announce its preliminary unaudited results on 9 April 2024 and will announce further updates to its business development and capital allocation strategies at that time.
As of 31 December 2023, Identicare had net liabilities of approximately £6.9m and for the 12 months to 31 December 2023, an EBITDA* of approximately £1.7m and profit before tax of approximately £0.1m.
Jenny Winter, directora ejecutiva, comentó: "I'm very proud to see what we have achieved with Identicare in recent years. Today's decision to crystallise the value from the sale is the logical next step, significantly strengthening our balance sheet and giving us additional financial flexibility and firepower as we concentrate on growing our pharmaceutical-focused animal health business."
Notas
Identicare financials are taken from December management accounts and are unaudited.
* EBITDA is defined as earnings before interest, tax, depreciation, amortisation, exceptional items and share based payments.
Acerca de Animalcare
Animalcare Group plc es una organización de marketing y ventas veterinarias internacionales que cotiza en AIM en el Reino Unido. Animalcare opera en siete países y exporta a aproximadamente 40 países en Europa y en todo el mundo. El Grupo se centra en llevar productos nuevos e innovadores al mercado a través de su propia línea de desarrollo, asociaciones y mediante adquisiciones.
For more information about Animalcare, please visit www.animalcaregroup.com or contact:
grupo animalcare plc Jenny Winter, directora ejecutiva Chris Brewster, director financiero Relaciones con los medios/inversionistas
| 44 0 1904 487 687
|
Stifel Nicolaus Europa limitada ben madison Nicolás Harland francisco norte
| 44 0 20 7710 7600 |
panmure gordon (Articulación Broker) Finanzas Corporativas Freddy Crossley / Emma Earl Corretaje corporativo Rupert Dearden
| 44 0 20 7886 2500 |
RNS puede usar su dirección IP para confirmar el cumplimiento de los términos y condiciones, para analizar cómo interactúa con la información contenida en esta comunicación y para compartir dicho análisis de forma anónima con otros como parte de nuestros servicios comerciales. Para obtener más información sobre cómo RNS y la Bolsa de Valores de Londres utilizan los datos personales que nos proporciona, consulte nuestra Política de privacidad.